These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2501333)

  • 1. Determination of the thalidomide analogues 2-(2,6-dioxopiperidine-3-yl)phthalimidine (EM 12), 2-(2,6-dioxopiperidine-4-yl)phthalimidine (EM 16) and their metabolites in biological samples.
    Winckler K; Klinkmüller KD; Schmahl HJ
    J Chromatogr; 1989 Mar; 488(2):417-25. PubMed ID: 2501333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enantiomers of the teratogenic thalidomide analogue EM 12. 2. Chemical stability, stereoselectivity of metabolism and renal excretion in the marmoset monkey.
    Schmahl HJ; Heger W; Nau H
    Toxicol Lett; 1989 Jan; 45(1):23-33. PubMed ID: 2492686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey.
    Schmahl HJ; Nau H; Neubert D
    Arch Toxicol; 1988; 62(2-3):200-4. PubMed ID: 3143339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
    Luzzio FA; Mayorov AV; Ng SS; Kruger EA; Figg WD
    J Med Chem; 2003 Aug; 46(18):3793-9. PubMed ID: 12930142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation.
    Eriksson T; Björkman S; Fyge A; Ekberg H
    J Chromatogr; 1992 Nov; 582(1-2):211-6. PubMed ID: 1491043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Embryotoxic effects of thalidomide derivatives on the non-human primate Callithrix jacchus; 3. Teratogenic potency of the EM 12 enantiomers.
    Heger W; Klug S; Schmahl HJ; Nau H; Merker HJ; Neubert D
    Arch Toxicol; 1988; 62(2-3):205-8. PubMed ID: 3196154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography.
    Huang YJ; Liao JF; Tsai TH
    Biomed Chromatogr; 2005 Sep; 19(7):488-93. PubMed ID: 15651096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse.
    Schmahl HJ; Dencker L; Plum C; Chahoud I; Nau H
    Arch Toxicol; 1996; 70(11):749-56. PubMed ID: 8896721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide.
    Helm FC; Frankus E; Friderichs E; Graudums I; Flohé L
    Arzneimittelforschung; 1981; 31(6):941-9. PubMed ID: 7196239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat.
    Yang X; Hu Z; Chan SY; Ho PC; Chan E; Duan W; Goh BC; Zhou S
    J Pharm Biomed Anal; 2005 Sep; 39(1-2):299-304. PubMed ID: 16085147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of thalidomide in rabbits and rats.
    Schumacher H; Blake DA; Gillette JR
    J Pharmacol Exp Ther; 1968 Mar; 160(1):201-11. PubMed ID: 5639105
    [No Abstract]   [Full Text] [Related]  

  • 12. Determination of thalidomide and its major metabolites by high-performance liquid chromatography.
    Czejka MJ; Koch HP
    J Chromatogr; 1987 Jan; 413():181-7. PubMed ID: 3558667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in analytical determination of thalidomide and its metabolites.
    Bosch ME; Sánchez AJ; Rojas FS; Ojeda CB
    J Pharm Biomed Anal; 2008 Jan; 46(1):9-17. PubMed ID: 18023317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay.
    Jiang F; Peng X; Cai D; Wen D; Liu Y; Zhi M; Chen J; Hu P; Wang X; Gao Y; Huang M; Gao X; Zhong G
    Biomed Chromatogr; 2018 Aug; 32(8):e4240. PubMed ID: 29529709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study.
    Chen LG; Wang Z; Wang S; Li T; Pan Y; Lai X
    J Chromatogr Sci; 2016 Sep; 54(8):1336-40. PubMed ID: 27165568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide enantiomers: determination in biological samples by HPLC and vancomycin-CSP.
    Murphy-Poulton SF; Boyle F; Gu XQ; Mather LE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):48-56. PubMed ID: 16321578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of (4-(1,3-dioxo-1,3-dihydro-2H-isoindol- 2-yl)-N'-[(4-ethoxyphenyl) methylidene] benzohydrazide, a novel anti-inflammatory agent, in biological fluids by UPLC-MS/MS: Assay development, validation and in vitro metabolic stability study.
    Iqbal M; Bhat MA; Raish M; Ezzeldin E
    Biomed Chromatogr; 2017 Oct; 31(10):. PubMed ID: 28370149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man.
    Eriksson T; Björkman S; Roth B; Björk H; Höglund P
    J Pharm Pharmacol; 1998 Dec; 50(12):1409-16. PubMed ID: 10052858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Embryotoxic effects of thalidomide-derivatives in the non-human primate Callithrix jacchus. I. Effects of 3-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-dioxopiperidine (EM12) on skeletal development.
    Merker HJ; Heger W; Sames K; Stürje H; Neubert D
    Arch Toxicol; 1988 Jan; 61(3):165-79. PubMed ID: 3355362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of thalidomide by high performance liquid chromatography: methodological strategy for clinical trials.
    Lyon AW; Duran G; Raisys VA
    Clin Biochem; 1995 Aug; 28(4):467-70. PubMed ID: 8521603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.